Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 04 symbols : ABBV save search
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights– Virtual investor event to take place on Monday, June 7, 2021 at 6 p.m. ET –
Published: 2021-06-04 (Crawled : 23:00) - biospace.com/
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
CHRS | $2.22 -0.45% -0.45% 2.2M
|
Health Technology
|
| O: 7.36%
H: 1.43%
C: -5.21%
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights
Published: 2021-06-04 (Crawled : 22:00) - globenewswire.com
CHRS | $2.22 -0.45% -0.45% 2.2M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
| Email alert
Add to watchlist
bioscience
Global $53 Bn Psoriasis Drugs Markets 2021-2030: Biologic Drugs, Small-Molecule Systemic Drugs, Topical Therapies, TNF-Alpha, PDE4, & Interleukin Inhibitors, Oral, Parenteral, Topical
Published: 2021-06-04 (Crawled : 21:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.63 -1.48% 0.0% 3.2M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
| Email alert
Add to watchlist
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
| Email alert
Add to watchlist
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
| Email alert
Add to watchlist
drug psoriasis therapy
Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
Published: 2021-06-04 (Crawled : 13:15) - prnewswire.com
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
leukemia
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2021-06-04 (Crawled : 01:00) - globenewswire.com
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
CHRS | $2.22 -0.45% -0.45% 2.2M
|
Health Technology
|
| O: 7.36%
H: 1.43%
C: -5.21%
treatment therapy
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.